IT 9302

Drug Profile

IT 9302

Latest Information Update: 08 Sep 2006

Price : $50

At a glance

  • Originator Amersham
  • Class Anti-inflammatories
  • Mechanism of Action Interleukin 10 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Pancreatitis

Most Recent Events

  • 08 Sep 2006 Discontinued - Preclinical for Pancreatitis (unspecified route)
  • 02 Dec 2003 No development reported - Preclinical for Pancreatitis (unspecified route)
  • 19 May 2000 Two studies were added to the preclinical pharmacodynamics section (809615; 809616)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top